Roche Diagnostics and OraSure Technologies Sign Letter of Intent to Develop Fully Automated Oral Fluid Drugs of Abuse Assays

This partnership will enable laboratories to increase efficiencies while

offering an improved level of service by providing quicker turnaround times



Oct 04, 2006, 01:00 ET from Roche Diagnostics

    INDIANAPOLIS, Oct. 4 /PRNewswire/ -- Roche Diagnostics today signed a
 letter of intent to negotiate an agreement for the joint development and
 commercialization of homogeneous fully-automated oral fluid drugs of abuse
 assays that can run on random access chemistry analyzers with OraSure
 Technologies, Inc. (Nasdaq:   OSUR). The oral fluid assays will be developed
 for use with OraSure's Intercept(R) oral specimen collection device and
 Roche's KIMS (kinetic interaction of microparticles in solution)
 technology. The oral fluid assays will be designed to run on various
 automated analyzers and to allow oral fluid samples to be processed with
 the same efficiency as current urine based tests. Among the key potential
 benefits to laboratories will be increased efficiencies and quicker
 turnaround times.
     "With automation of oral fluid testing becoming increasingly important,
 Roche is committed to providing best-in-class high throughput oral fluid
 solutions for our customers. We are very pleased to be collaborating with
 OraSure Technologies in the development of fully automated oral fluid drugs
 of abuse assays," said Joe Passarelli, Vice President of Research and
 Development at Roche Diagnostics. "This partnership would leverage the
 strengths of both companies including OraSure's market leading Intercept(R)
 Drug Test and Roche Diagnostics' fully automated ONLINE DAT(R) drug
 screening portfolio -- leading to an integrated product offering from a
 single source," he added.
     "The development of automated assays for oral fluid drugs of abuse
 testing is technologically a very important step for OraSure and its
 laboratory customers," said Stephen R. Lee, Ph.D., Executive Vice President
 and Chief Science Officer, OraSure Technologies. "It will enable them to
 run these assays on the most advanced, flexible chemistry analyzers used in
 laboratories today, which should ultimately lead to higher volumes of oral
 fluid testing. We are extremely excited to be working with Roche on this
 project -- their industry-leading KIMS technology combined with their
 system reliability is ideally suited for this application," said Lee.
     Developed and manufactured by OraSure Technologies, the Intercept(R)
 device is the only FDA-cleared invitro diagnostic laboratory-based oral
 fluid testing system used for detecting commonly abused drugs such as
 marijuana, cocaine, opiates, PCP and amphetamines (including
 methamphetamine and ecstasy) and for detecting barbiturates, methadone and
 benzodiazepines. Intercept(R) testing is currently being used in workplace,
 drug treatment and criminal justice testing markets, as well as in public
 school systems.
     With over twenty-five years of proven experience in the drugs of abuse
 market, Roche Diagnostics has established itself as a global leader. Roche
 offers a full portfolio of testing solutions including ONLINE DAT(R) drugs
 of abuse screening assays combined with system platforms that are tailored
 for various customer segment and volume requirements.
     About Roche
     Headquartered in Basel, Switzerland, Roche is one of the world's
 leading research-focused healthcare groups in the fields of pharmaceuticals
 and diagnostics. As a supplier of innovative products and services for the
 early detection, prevention, diagnosis and treatment of disease, the Group
 contributes on a broad range of fronts to improving people's health and
 quality of life. Roche is a world leader in diagnostics, the leading
 supplier of medicines for cancer and transplantation and a market leader in
 virology. In 2005, sales by the Pharmaceuticals Division totaled 27.3
 billion Swiss francs, and the Diagnostics Division posted sales of 8.2
 billion Swiss francs. Roche employs roughly 70,000 people in 150 countries
 and has R&D agreements and strategic alliances with numerous partners,
 including majority ownership interests in Genentech and Chugai. Roche's
 Diagnostics Division offers a uniquely broad product portfolio and supplies
 a wide array of innovative testing products and services to researchers,
 physicians, patients, hospitals and laboratories world-wide. Roche
 Centralized Diagnostics, a business area of Roche Diagnostics, is a leading
 force in developing and supplying new technologies and integrated solutions
 that help clinical laboratories to operate efficiently and cost
 effectively. For further information, please visit our website at
 http://www.roche-diagnostics.us .
     About OraSure Technologies
     OraSure Technologies develops, manufactures and markets oral fluid
 specimen collection devices using proprietary oral fluid technologies,
 diagnostic products including immunoassays, and other medical devices.
 These products are sold in the United States as well as internationally to
 various clinical laboratories, hospitals, clinics, community-based
 organizations and other public health organizations, distributors,
 government agencies, physicians' offices, and commercial and industrial
 entities.
     OraSure Technologies manufactures and sells Intercept(R), the only
 FDA-cleared in vitro diagnostic oral fluid testing system used for
 detecting commonly abused drugs such as marijuana, cocaine, opiates, PCP
 and amphetamines (including methamphetamine and ecstasy) and for detecting
 barbiturates, methadone and benzodiazepines. For more information on the
 Company, please go to http://www.orasure.com .
     All trademarks used or mentioned in this release are protected by law.
 
     For further information please contact:
 
     Doyia Turner
     Corporate Communications, Roche Diagnostics
     Phone: 317-521-7252
     Email: doyia.turner@roche.com
 
     Ron Ticho
     OraSure Technologies
     Phone: 610-882-1820 ext. 3013
     Email : rticho@orasure.com
 
 

SOURCE Roche Diagnostics
    INDIANAPOLIS, Oct. 4 /PRNewswire/ -- Roche Diagnostics today signed a
 letter of intent to negotiate an agreement for the joint development and
 commercialization of homogeneous fully-automated oral fluid drugs of abuse
 assays that can run on random access chemistry analyzers with OraSure
 Technologies, Inc. (Nasdaq:   OSUR). The oral fluid assays will be developed
 for use with OraSure's Intercept(R) oral specimen collection device and
 Roche's KIMS (kinetic interaction of microparticles in solution)
 technology. The oral fluid assays will be designed to run on various
 automated analyzers and to allow oral fluid samples to be processed with
 the same efficiency as current urine based tests. Among the key potential
 benefits to laboratories will be increased efficiencies and quicker
 turnaround times.
     "With automation of oral fluid testing becoming increasingly important,
 Roche is committed to providing best-in-class high throughput oral fluid
 solutions for our customers. We are very pleased to be collaborating with
 OraSure Technologies in the development of fully automated oral fluid drugs
 of abuse assays," said Joe Passarelli, Vice President of Research and
 Development at Roche Diagnostics. "This partnership would leverage the
 strengths of both companies including OraSure's market leading Intercept(R)
 Drug Test and Roche Diagnostics' fully automated ONLINE DAT(R) drug
 screening portfolio -- leading to an integrated product offering from a
 single source," he added.
     "The development of automated assays for oral fluid drugs of abuse
 testing is technologically a very important step for OraSure and its
 laboratory customers," said Stephen R. Lee, Ph.D., Executive Vice President
 and Chief Science Officer, OraSure Technologies. "It will enable them to
 run these assays on the most advanced, flexible chemistry analyzers used in
 laboratories today, which should ultimately lead to higher volumes of oral
 fluid testing. We are extremely excited to be working with Roche on this
 project -- their industry-leading KIMS technology combined with their
 system reliability is ideally suited for this application," said Lee.
     Developed and manufactured by OraSure Technologies, the Intercept(R)
 device is the only FDA-cleared invitro diagnostic laboratory-based oral
 fluid testing system used for detecting commonly abused drugs such as
 marijuana, cocaine, opiates, PCP and amphetamines (including
 methamphetamine and ecstasy) and for detecting barbiturates, methadone and
 benzodiazepines. Intercept(R) testing is currently being used in workplace,
 drug treatment and criminal justice testing markets, as well as in public
 school systems.
     With over twenty-five years of proven experience in the drugs of abuse
 market, Roche Diagnostics has established itself as a global leader. Roche
 offers a full portfolio of testing solutions including ONLINE DAT(R) drugs
 of abuse screening assays combined with system platforms that are tailored
 for various customer segment and volume requirements.
     About Roche
     Headquartered in Basel, Switzerland, Roche is one of the world's
 leading research-focused healthcare groups in the fields of pharmaceuticals
 and diagnostics. As a supplier of innovative products and services for the
 early detection, prevention, diagnosis and treatment of disease, the Group
 contributes on a broad range of fronts to improving people's health and
 quality of life. Roche is a world leader in diagnostics, the leading
 supplier of medicines for cancer and transplantation and a market leader in
 virology. In 2005, sales by the Pharmaceuticals Division totaled 27.3
 billion Swiss francs, and the Diagnostics Division posted sales of 8.2
 billion Swiss francs. Roche employs roughly 70,000 people in 150 countries
 and has R&D agreements and strategic alliances with numerous partners,
 including majority ownership interests in Genentech and Chugai. Roche's
 Diagnostics Division offers a uniquely broad product portfolio and supplies
 a wide array of innovative testing products and services to researchers,
 physicians, patients, hospitals and laboratories world-wide. Roche
 Centralized Diagnostics, a business area of Roche Diagnostics, is a leading
 force in developing and supplying new technologies and integrated solutions
 that help clinical laboratories to operate efficiently and cost
 effectively. For further information, please visit our website at
 http://www.roche-diagnostics.us .
     About OraSure Technologies
     OraSure Technologies develops, manufactures and markets oral fluid
 specimen collection devices using proprietary oral fluid technologies,
 diagnostic products including immunoassays, and other medical devices.
 These products are sold in the United States as well as internationally to
 various clinical laboratories, hospitals, clinics, community-based
 organizations and other public health organizations, distributors,
 government agencies, physicians' offices, and commercial and industrial
 entities.
     OraSure Technologies manufactures and sells Intercept(R), the only
 FDA-cleared in vitro diagnostic oral fluid testing system used for
 detecting commonly abused drugs such as marijuana, cocaine, opiates, PCP
 and amphetamines (including methamphetamine and ecstasy) and for detecting
 barbiturates, methadone and benzodiazepines. For more information on the
 Company, please go to http://www.orasure.com .
     All trademarks used or mentioned in this release are protected by law.
 
     For further information please contact:
 
     Doyia Turner
     Corporate Communications, Roche Diagnostics
     Phone: 317-521-7252
     Email: doyia.turner@roche.com
 
     Ron Ticho
     OraSure Technologies
     Phone: 610-882-1820 ext. 3013
     Email : rticho@orasure.com
 
 SOURCE Roche Diagnostics